强直性脊柱炎的发病机制与MIF及TGF-β在其中的研究进展

doi:10.3969/j.issn.1004-583X.2025.10.013

摘要/Abstract

摘要：

强直性脊柱炎(ankylosingSpondylitis,AS)是一种以炎性腰背痛为主要特征的自身免疫性疾病,主要侵袭中轴关节并可累及外周关节及多种器官,严重情况下导致脊柱强直或畸形,严重影响患者的生活质量和身体健康。AS的病理特征主要包括炎症反应、骨破坏和异位骨化。其发病因素复杂多样,涉及遗传背景、免疫调节异常、感染、人类白细胞组织相容性抗原(HLA-B27)以及微生物群等多个方面。但鉴于AS具有独特的遗传倾向和发病模式,本综述旨在深入探讨和解释AS发病机制的多种假说,并特别关注巨噬细胞迁移抑制因子(MIF)及转化生长因子β(TGF-β)在AS发病过程中的潜在作用。

关键词: 脊柱炎, 强直性, HLB-27, 巨噬细胞迁移抑制因子, 转化生长因子β

中图分类号:

R593.23

贺丹婷, 孟景红. 强直性脊柱炎的发病机制与MIF及TGF-β在其中的研究进展[J]. 临床荟萃, 2025, 40(10): 954-960.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2025.10.013

https://www.lchc.cn/CN/Y2025/V40/I10/954

参考文献 39

[1]	中华医学会风湿病学分会. 强直性脊柱炎诊断及治疗指南[J]. 中华风湿病学杂志2021, 14(8):557-559.
[2]	Li H, Guo Q, Zhou S, et al. Corrigendum to: An account on the history of pharmacology in Spain[J]. Pharmacol Res, 2024, 208:107365.doi: 10.1016/j.phrs.2024.107365.
[3]	Kim SH, Lee SH. Updates on ankylosing spondylitis: Pathogenesis and therapeutic agents[J]. J Rheum Dis, 2023, 30(4):220-233.doi: 10.4078/jrd.2023.0041.
[4]	Bilski R, Kamiński P, Kupczyk D, et al. Environmental and genetic determinants of ankylosing spondylitis[J]. Int J Mol Sci, 2024, 25(14):7814.doi: 10.3390/ijms25147814.
[5]	Chen CW, Wei JC, et al. Editorial: Advances in pathogenesis, etiology, and therapies for ankylosing spondylitis[J]. Front Immunol, 2021, 12:822582.doi: 10.3389/fimmu.2021.822582.
[6]	Xiong Y, Cai M, Xu Y, et al. Joint together: The etiology and pathogenesis of ankylosing spondylitis[J]. Front Immunol, 2022, 13:996103.doi: 10.3389/fimmu.2022.996103.
[7]	Wei Y, Zhang S, Shao F, et al. Ankylosing spondylitis: From pathogenesis to therapy[J]. Int Immunopharmacol, 2025, 145:113709.doi: 10.1016/j.intimp.2024.113709.
[8]	Chen B, Li J, He C, et al. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review)[J]. Mol Med Rep, 2017, 15(4):1943-1951.doi: 10.3892/mmr.2017.6248. pmid: 28259985
[9]	Khan MA. HLA-B*27 and ankylosing spondylitis: 50 years of insights and discoveries[J]. Curr Rheumatol Rep, 2023, 25(12):327-340.doi: 10.1007/s11926-023-01118-5. pmid: 37950822
[10]	Pedersen SJ, Maksymowych WP. The pathogenesis of ankylosing spondylitis: An update[J]. Curr Rheumatol, 2019, 21(10):58.doi: 10.1007/s11926-019-0856-3.
[11]	Colbert RA, Tran TM, Layh-Schmitt G. HLA-B27 misfolding and ankylosing spondylitis[J]. Mol Immunol, 2014, 57(1):44-51.doi: 10.1016/j.molimm.2013.07.013. pmid: 23993278
[12]	Ranganathan V, Gracey E, Brown MA, et al. Pathogenesis of ankylosing spondylitis-recent advances and future directions[J]. Nat Rev Rheumatol, 2017, 13(6):359-367.doi: 10.1038/nrrheum.2017.56. pmid: 28446810
[13]	Braun J, Sieper J. Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis[J]. RMD Open, 2023, 9(3):e003102.doi: 10.1136/rmdopen-2023-003102.
[14]	Mathew A, Bhagavaldas MC, Biswas R, et al. Genetic risk factors in ankylosing spondylitis: Insights into etiology and disease pathogenesis[J]. Int J Rheum Dis, 2023, 27(1): e15023-e15023.doi: 10.1111/1756-185X.15023.
[15]	Saad MA, Abdul-Sattar AB, Abdelal IT, et al. Shedding light on the role of ERAP1 in axial spondyloarthritis[J]. Cureus, 2023, 15(11):e48806.doi: 10.7759/cureus.48806.
[16]	Sharip A, Kunz J. Understanding the pathogenesis of spondyloarthritis[J]. Biomolecules, 2020, 10(10):1461.doi: 10.3390/biom10101461.
[17]	Song ZY, Yuan D, Zhang SX. Role of the microbiome and its metabolites in ankylosing spondylitis[J]. Front Immunol, 2022, 13:1010572.doi: 10.3389/fimmu.2022.1010572.
[18]	Long F, Wang T, Li Q, et al. Association between Klebsiella pneumoniae and ankylosing spondylitis: A systematic review and meta-analysis[J]. Int J Rheum Dis, 2022, 25(4):422-432.doi: 10.1111/1756-185X.14283. pmid: 35019225
[19]	Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitis--insights into pathogenesis[J]. Nat Rev Rheumatol, 2016, 12(2):81-91.doi: 10.1038/nrrheum.2015.133. pmid: 26439405
[20]	Simone D, Al Mossawi MH, Bowness P. Progress in our understanding of the pathogenesis of ankylosing spondylitis[J]. Rheumatology (Oxford), 2018, 57(suppl_6):vi4-vi9.doi: 10.1093/rheumatology/key001.
[21]	Sumaiya K, Langford D, Natarajaseenivasan K, et al. Macrophage migration inhibitory factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategies[J]. Pharmacol Ther, 2022, 233:108024.doi: 10.1016/j.pharmthera.2021.108024.
[22]	谢小青, 刘亚贤, 王俊科. 巨噬细胞迁移抑制因子(MIF)在肿瘤免疫应答过程中的研究进展[J]. 细胞与分子免疫学杂志, 2024, 40(6): 561-565.doi: 10.13423/j.cnki.cjcmi.009725.
[23]	Song S, Xiao Z, Dekker FJ, et al. Macrophage migration inhibitory factor family proteins are multitasking cytokines in tissue injury[J]. Cell Mol Life Sci, 2022, 79(2):105.doi: 10.1007/s00018-021-04038-8. pmid: 35091838
[24]	Camacho Meza G, Avalos Navarro G, De La Cruz Mosso U, et al. Macrophage migration inhibitory factor: Exploring physiological roles and comparing health benefits against oncogenic and autoimmune risks (Review)[J]. Int J Mol Med, 2025, 56(4):149.doi: 10.3892/ijmm.2025.5590.
[25]	Kim KW, Kim HR. Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis[J]. Korean J Intern Med, 2016, 31(4):634-642.doi: 10.3904/kjim.2016.098.
[26]	Santos LL, Morand EF. The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis[J]. Wien Med Wochenschr, 2006, 156(1-2):11-18.doi: 10.1007/s10354-005-0243-8. pmid: 16465610
[27]	Ranganathan V, Ciccia F, Zeng F, et al. Macrophage migration inhibitory factor induces inflammation and predicts spinal progression in ankylosing spondylitis[J]. Arthritis Rheumatol, 2017, 69(9):1796-1806.doi: 10.1002/art.40175.
[28]	Kozaci LD, Sari I, Alacacioglu A, et al. Evaluation of inflammation and oxidative stress in ankylosing spondylitis: A role for macrophage migration inhibitory factor[J]. Mod Rheumatol, 2010, 20(1):34-39.doi: 10.1007/s10165-009-0230-9. pmid: 19787418
[29]	Onuora S. Spondyloarthropathies: MIF drives inflammation and bone formation in AS[J]. Nat Rev Rheumatol, 2017, 13(8):451.doi: 10.1038/nrrheum.2017.91. pmid: 28660909
[30]	Frangogiannis N. Transforming growth factor-β in tissue fibrosis[J]. J Exp Med, 2020, 217(3):e20190103.doi: 10.1084/jem.20190103.
[31]	Deng Z, Fan T, Xiao C, et al. TGF-β signaling in health, disease, and therapeutics[J]. Signal Transduct Target Ther, 2024, 9(1):61.doi: 10.1038/s41392-024-01764-w.
[32]	Zelisko N, Lesyk R, Stoika R. Structure, unique biological properties, and mechanisms of action of transforming growth factor β[J]. Bioorg Chem, 150:107611.doi: 10.1016/j.bioorg.2024.107611.
[33]	Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: The master regulator of fibrosis[J]. Nat Rev Nephrol, 2016, 12(6):325-338.doi: 10.1038/nrneph.2016.48.
[34]	王庆文, 曾沛英, 蔡月明, 等. 转化生长因子β1/结缔组织生长因子通路在强直性脊柱炎中的表达[J]. 北京大学学报(医学版), 2012, 44(2):244-249.doi:10.3969/j.issn.1671-167X.2012.02.018.
[35]	董莹莹. 血清IL-34、TGF-β1和TGF-β2水平对强直性脊柱炎的诊断价值[J]. 中国民康医学, 2022, 34(15):129-132.doi:10.3969/j.issn.1672-0369.2022.15.038.
[36]	许红飞, 初同伟, 张超, 等. 转化生长因子β1在强直性脊柱炎患者黄韧带和椎旁肌中的表达[J]. 中国免疫学杂志, 2013, 29(4):344-346.
[37]	沈健, 张雨涵, 曹芳蕾, 等. 强直性脊柱炎患者血清RANKL、TGF-β1和TGF-β2的表达及临床意义[J]. 陕西医学杂志, 2019, 48(8):981-983.doi:10.3969/j.issn.1000-7377.2019.08.005.
[38]	Peng D, Fu M, Wang M, et al. Targeting TGF-β signal transduction for fibrosis and cancer therapy[J]. Mol Cancer, 2022, 21(1):104.doi: 10.1186/s12943-022-01569-x. pmid: 35461253
[39]	Ren LL, Li XJ, Duan TT, et al. Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities[J]. Chem Biol Interact, 2023, 369:110289.doi: 10.1016/j.cbi.2022.110289.

强直性脊柱炎的发病机制与MIF及TGF-β在其中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 39

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张瑾;宋宁;高耐芬;杨丛丽;吕侯强;杜博英. 孟鲁司特钠联合布地奈德对咳嗽变异性哮喘患儿血清转化生长因子β1和血清淀粉样蛋白A水平的影响[J]. 临床荟萃, 2015, 30(11): 1273-1.27513e+007.
[2]	刘香锟;侯超;王勇. 转化生长因子β1联合尿微量白蛋白在高血压肾病中的诊断价值[J]. 临床荟萃, 2014, 29(8): 928-929.
[3]	宋云肖;杨建柱;方洁;李琰;张金巧;孙丽霞. 脐血与健康供者骨髓中血管内皮生长因子和转化生长因子β1水平的比较[J]. 临床荟萃, 2014, 29(2): 165-167.
[4]	盖磊;李惠萍. 三氧化二砷对转化生长因子β1诱导的大鼠肺成纤维细胞增殖的影响[J]. 临床荟萃, 2013, 28(7): 769-771779.
[5]	刘欣燕;戴献利;侯志华;刘颖. 回生口服液对非小细胞肺癌疗效及转化生长因子β1和血管内皮生成因子影响的研究[J]. 临床荟萃, 2013, 28(6): 643-645.
[6]	李立. 苦参素在防治器官纤维化中的研究进展[J]. 临床荟萃, 2012, 27(6): 550-552.
[7]	徐丰博;刘惠兰;孙懿. 血浆纤溶酶原激活物抑制物1及血清转化生长因子β与2型糖尿病肾病的相关性研究[J]. 临床荟萃, 2012, 27(3): 210-212216.
[8]	薛国华;麦培培;段卫星;马惠芳. 特发性肺动脉高压侯选基因的相关研究进展[J]. 临床荟萃, 2012, 27(3): 267-269.
[9]	任苗苗;杜玄一. 转化生长因子β在慢性肾脏病中的作用[J]. 临床荟萃, 2012, 27(24): 2184-2188.
[10]	朱斌;王永霞;陈珅. 急性冠状动脉综合征患者血浆心钠素和转化生长因子β1的变化[J]. 临床荟萃, 2012, 27(17): 1488-1491.
[11]	庞晓璐;王丽丽;孟凡茹;王莉华;王东;高志英. 连续性血液净化治疗对转化生长因子β及T淋巴细胞亚群表达的影响[J]. 临床荟萃, 2012, 27(12): 1027-1031.
[12]	杨岩;赖娅芳;盛?燮?张小亚. 慢性乙型肝炎患者乙型肝炎病毒共价闭合环状DNA定量与血清中γ干扰素、白细胞介素10、转化生长因子β1水平的关系[J]. 临床荟萃, 2010, 25(10): 839-841.
[13]	孙丽霞;杨建柱;张金巧;吕鸿雁;宋晓宁;王金铠. 自身免疫性溶血性贫血患者转化生长因子β1和白细胞介素10的水平变化及其临床意义[J]. 临床荟萃, 2009, 24(19): 1702-1704.
[14]	周转. 慢性乙型肝炎患者血清转化生长因子β1、血小板衍生生长因子BB、基质金属蛋白酶2、基质金属蛋白酶抑制因子1与肝纤维化的关系研究[J]. 临床荟萃, 2009, 24(12): 1062-1063.
[15]	杨林;段惠军;王建荣;杨万霞;傅淑霞. IgA肾病患者血、尿骨形成蛋白7和转化生长因子β1水平的变化及其意义[J]. 临床荟萃, 2008, 23(9): 621-624.